Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HACS1
- Development stage
- Preclinical
- Lead developer
- University of Toronto
- Modality
- Small Molecules
01
Overview
HACS1 (Hematopoietic Adaptor-Containing SH3 and SAM domains), also known as SAMSN1, is an adaptor protein that functions as a tumor suppressor in the context of multiple myeloma (MM). It acts as a negative regulator of the IL-4 signaling axis and plays a critical role in modulating the bone marrow microenvironment. Research presented at ASH 2025 indicates that HACS1 deficiency (Hacs1-/-) leads to the accumulation of pro-tumorigenic myeloid-derived suppressor cells (MDSCs), upregulated PD-L1 expression, and suppressed T-cell activity. Conversely, the therapeutic stimulation or overexpression of HACS1 has been shown to reduce MDSC accumulation, enhance T-cell function, and decrease tumor burden. HACS1 is being investigated as a therapeutic target, with HACS1 agonists or stimulators potentially serving to overcome the immunosuppressive microenvironment in multiple myeloma.
- Other names
- SAMSN1SAMSN-1SAMSN 1SAM domain, SH3 domain and nuclear localization signals protein 1NASH1NASH-1NASH 1SASH2SASH-2SASH 2HACS-1HACS1HACS 1
Beyond the preview
Go deeper on HACS1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HACS1.